We are live on ! Find out more
VPC

Vestal Point Capital Portfolio holdings

AUM $3.58B
1-Year Est. Return 189.12%
This Fund
S&P 500
This Quarter Est. Return
+0.42%
1 Year Est. Return
+189.12%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$1.9B
AUM Growth
+$499M
Cap. Flow
+$505M
Cap. Flow %
26.59%
Top 10 Hldgs %
45.18%
Holding
85
New
22
Increased
26
Reduced
12
Closed
13

Top Buys

Rank Stock Value
1
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$130M
2
FOLD
Amicus Therapeutics
FOLD
+$49.2M
3
ALC icon
Alcon
ALC
+$47.1M
4
RVMD icon
Revolution Medicines
RVMD
+$46.1M
5
EXAS
Exact Sciences
EXAS
+$35.6M

Top Sells

Rank Stock Value
1
INSM icon
Insmed
INSM
+$82M
2
URGN icon
UroGen Pharma
URGN
+$23.8M
3
RARE icon
Ultragenyx Pharmaceutical
RARE
+$18.1M
4
LQDA icon
Liquidia Corp
LQDA
+$18.1M
5
ESTA icon
Establishment Labs
ESTA
+$17.7M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SVRA icon
26
Savara
SVRA
$1.13B
$25.1M 1.32%
11,015,000
+15,000
+0.1% +$40.8K
COO icon
27
Cooper Companies
COO
$14.4B
$24.9M 1.31%
+350,000
New +$26.8M
GPCR icon
28
Structure Therapeutics
GPCR
$3.51B
$24.9M 1.31%
1,200,000
-588,990
-33% -$13M
CDTX
29
DELISTED
Cidara Therapeutics
CDTX
$24.4M 1.28%
500,000
-4,542
-0.9% -$109K
ATXS
30
DELISTED
Astria Therapeutics
ATXS
$24.2M 1.28%
4,522,000
+342,000
+8% +$1.66M
ABT icon
31
Abbott
ABT
$182B
$23.8M 1.25%
+175,000
New +$23.1M
EW icon
32
Edwards Lifesciences
EW
$51.3B
$23.5M 1.24%
+300,000
New +$22.4M
NRIX icon
33
Nurix Therapeutics
NRIX
$2.47B
$22.8M 1.2%
2,000,000
+874,448
+78% +$9.45M
COGT icon
34
Cogent Biosciences
COGT
$7.15B
$22.1M 1.16%
3,080,000
+80,000
+3% +$443K
BRKR icon
35
Bruker
BRKR
$8.11B
$20.6M 1.08%
500,000
+200,000
+67% +$7.72M
IONS icon
36
Ionis Pharmaceuticals
IONS
$9.05B
$19.8M 1.04%
+500,000
New +$16.4M
DAWN
37
DELISTED
Day One Biopharmaceuticals
DAWN
$19.5M 1.03%
3,000,000
+401,873
+15% +$2.76M
MDT icon
38
Medtronic
MDT
$109B
$17M 0.89%
+195,000
New +$16.5M
PRGO icon
39
Perrigo
PRGO
$1.43B
$16.7M 0.88%
625,000
+37,351
+6% +$978K
ZYME icon
40
Zymeworks
ZYME
$1.64B
$14.4M 0.76%
1,150,000
+650,000
+130% +$7.74M
BDTX icon
41
Black Diamond Therapeutics
BDTX
$101M
$13.9M 0.73%
5,600,000
– –
LXEO icon
42
Lexeo Therapeutics
LXEO
$342M
$13M 0.68%
3,228,161
+2,091,912
+184% +$6.88M
NYXH
43
Nyxoah
NYXH
$145M
$10.5M 0.55%
1,402,002
-916,952
-40% -$6.3M
TMO icon
44
Thermo Fisher Scientific
TMO
$210B
$10.1M 0.53%
+25,000
New +$10.5M
DHR icon
45
Danaher
DHR
$137B
$9.88M 0.52%
50,000
-75,000
-60% -$14.5M
BBNX
46
Beta Bionics
BBNX
$627M
$8.01M 0.42%
+550,000
New +$7.79M
IRON icon
47
Disc Medicine
IRON
$2.98B
$7.41M 0.39%
+140,000
New +$6.58M
SLDB icon
48
Solid Biosciences
SLDB
$826M
$7.33M 0.39%
1,505,000
-248,558
-14% -$879K
TSHA icon
49
Taysha Gene Therapies
TSHA
$1.7B
$6.93M 0.36%
+3,000,000
New +$6.52M
DYN icon
50
Dyne Therapeutics
DYN
$4.82B
$6.93M 0.36%
727,500
-1,072,500
-60% -$11.8M
1
2
3 4

Similar funds

WWA
WCG Wealth Advisors Las Vegas, Nevada $3.57B AUM 18.63% 1-Year Est. Return
BPS
BNDES Participacoes SA Rio De Janeiro, Brazil $3.58B AUM
SPC
Sigma Planning Corp Ann Arbor, Michigan $3.6B AUM 24.57% 1-Year Est. Return
U
Uber San Francisco, California $3.6B AUM 19.81% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
AAP
Arax Advisory Partners Denver, Colorado $3.54B AUM 19.14% 1-Year Est. Return
SCM
Saba Capital Management New York $3.62B AUM 13% 1-Year Est. Return
ACM
Advent Capital Management New York $3.63B AUM 0.29% 1-Year Est. Return

Vestal Point Capital's Q2 2025 Portfolio in Review

As of Q2 2025, Vestal Point Capital held 85 positions worth $1.9B, up 36% from $1.4B the previous quarter. Its ten largest holdings account for 45% of the portfolio.

Vestal Point Capital deployed $505M of net new capital in Q2 2025, opening 22 new positions and adding to 26 existing holdings. Its largest new stake was Jazz Pharmaceuticals: 1,200,000 shares worth $127M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was uniQure, an estimated $14.7M trimmed.

  • Vestal Point Capital's largest Q2 2025 buy was Jazz Pharmaceuticals: 1,200,000 shares worth $127M.
  • Vestal Point Capital added most to Amicus Therapeutics in Q2 2025, an estimated $49.2M increase.
  • Vestal Point Capital's biggest Q2 2025 reduction was uniQure, cutting an estimated $14.7M.
  • Vestal Point Capital fully exited Insmed in Q2 2025, selling an estimated $82M.
  • Vestal Point Capital's ten largest holdings make up 45% of its $1.9B portfolio in Q2 2025.
  • Vestal Point Capital opened 22 new positions and closed 13 in Q2 2025.
  • Vestal Point Capital's portfolio value rose 36% quarter-over-quarter to $1.9B.

Based on Vestal Point Capital's 13F filing for Q2 2025, filed 14 Aug 2025.